Chronic xenogeneic GVHD after CAR T cell therapy limits long-term safety assessment of CAR effects using NSG mouse model [0.03%]
基于诺德grass小鼠模型的嵌合抗原受体T细胞治疗后慢性异基因移植物抗宿主病限制了长期评估嵌合抗原受体的效果的安全性
Wahed A Firoz,Michael K Sheng,Pedro Ruivo et al.
Wahed A Firoz et al.
The clinical successes of chimeric antigen receptor (CAR) T cells represent a major shift in immunotherapy. However, there is also increasing emphasis on potential long-term effects of CAR T cell therapy, especially using preclinical xenoge...
Modifying quality and equity of care: emerging roles of genetic disease modifiers in β-hemoglobinopathies [0.03%]
遗传代偿因子在β型地中海贫血中的新角色可改善治疗效果和公平性
Panayiota L Papasavva,Atinuke M Dosunmu-Ogunbi,Morohuntodun Oni et al.
Panayiota L Papasavva et al.
Genetic disease modifiers (GDMs) strongly affect disease and therapy outcomes, rendering their characterization essential for prognosis, treatment decisions, and therapy development. A paradigm for the importance of GDMs are β-hemoglobinop...
Endpoints for clinical allograft trials; GRFS should not be abandoned [0.03%]
临床同种异体移植试验的终点；不应放弃使用GRFS评分体系
Daniel J Weisdorf,Margaret L MacMillan,Regis Peffault de Latour et al.
Daniel J Weisdorf et al.
Mortality Prediction in Immune TTP Remains Challenging Despite AI Advances [0.03%]
人工智能进展仍难以攻克免疫性TTP的死亡率预测难题
Mouhamed Yazan Abou-Ismail,Meera Sridharan,Sanjana Kalvehalli Kashinath et al.
Mouhamed Yazan Abou-Ismail et al.
Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200 [0.03%]
用于多发性骨髓瘤自体移植的Evomela I/II期临床试验：方案优化与MEL200的匹配对照研究
Qaiser Bashir,Peter F Thall,Jitesh Kawedia et al.
Qaiser Bashir et al.
Melphalan 200 mg/m² is the standard conditioning regimen for autologous hematopoietic stem cell transplantation (ASCT) in multiple myeloma, but further dose escalation is limited by toxicity. Evomela, a propylene‑glycol-free melphalan wit...
Daniel Molin
Daniel Molin
Andrew Staron
Andrew Staron
Chromatin Accessibility Shapes Developmental-Specific Lineage Plasticity in Hematopoiesis [0.03%]
染色质可及性塑造造血过程中具有发育阶段特异性的谱系可塑性
Sara Palo,Keiki Nagaharu,Mikael N E Sommarin et al.
Sara Palo et al.
Cell differentiation is governed by dynamic changes in chromatin accessibility, and its dysregulation underlies multiple disease states. Prior to birth, development of the hematopoietic system constitutes a period of broad differentiation p...
Laura Palomo,Mireia Morgades,Manja Meggendorfer et al.
Laura Palomo et al.
Prognostication in chronic myelomonocytic leukemia (CMML) remains a challenge due to the biological complexity and variable clinical course of the disease. This study aimed to evaluate the prognostic utility of the International Prognostic ...